We sought to determine the role of Fc¦Ã receptor (Fc¦ÃR) IIa in IVIg-induced anaphylactoid reactions.
Neutrophils and PBMCs were isolated from healthy subjects and IVIg-treated patients. Fc¦ÃRIIa mRNA and DNA were analyzed by using real-time PCR and sequencing. IgG-mediated elastase release and intracellular Ca2+ mobilization were determined in neutrophils and transfected cell lines, respectively.
A novel splice variant of Fc¦ÃRIIa containing an expressed cryptic exon 6* (Fc¦ÃRIIaexon6?) was identified in our index patient. This exon is normally spliced out of all Fc¦ÃRII isoforms, except the inhibitory Fc¦ÃRIIb1. Compared with healthy control subjects, the heterozygous FCGR2Ac.742+871A>G mutation was more frequent in patients with CVID (n?= 53, P?<?.013). Expression in patients with CVID was associated with anaphylaxis on IVIg infusion (P?= .002). On screening of additional IVIg-treated patient cohorts, we identified 6 FCGR2Ac.742+871A>G allele-positive patients with Kawasaki disease (n?= 208) and 1 patient with idiopathic thrombocytopenia (n?= 93). None had adverse reactions to IVIg. Moreover, Fc¦ÃRIIaexon6? was also demonstrated in asymptomatic family members. Functional studies in primary cells and transfected murine cells demonstrated enhanced cellular activation by Fc¦ÃRIIaexon6? compared with its native form, as shown by increased elastase release and intracellular calcium mobilization.
A novel splice variant, Fc¦ÃRIIaexon6?, was characterized as a low-frequency allele, coding for a gain-of-function receptor for IgG. In the presence of immune complexes, Fc¦ÃRIIaexon6? can contribute to anaphylaxis in patients with CVID.